Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anaptysbio (ANAB) Liabilities and Shareholders Equity: 2016-2025

Historic Liabilities and Shareholders Equity for Anaptysbio (ANAB) over the last 9 years, with Sep 2025 value amounting to $353.1 million.

  • Anaptysbio's Liabilities and Shareholders Equity fell 28.44% to $353.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.6 billion, marking a year-over-year decrease of 10.39%. This contributed to the annual value of $483.8 million for FY2024, which is 6.95% up from last year.
  • Per Anaptysbio's latest filing, its Liabilities and Shareholders Equity stood at $353.1 million for Q3 2025, which was up 5.32% from $335.2 million recorded in Q2 2025.
  • Over the past 5 years, Anaptysbio's Liabilities and Shareholders Equity peaked at $643.1 million during Q4 2021, and registered a low of $335.2 million during Q2 2025.
  • Over the past 3 years, Anaptysbio's median Liabilities and Shareholders Equity value was $452.4 million (recorded in 2023), while the average stood at $448.1 million.
  • As far as peak fluctuations go, Anaptysbio's Liabilities and Shareholders Equity skyrocketed by 57.70% in 2022, and later decreased by 28.44% in 2025.
  • Over the past 5 years, Anaptysbio's Liabilities and Shareholders Equity (Quarterly) stood at $643.1 million in 2021, then dropped by 5.08% to $610.4 million in 2022, then dropped by 25.88% to $452.4 million in 2023, then grew by 6.95% to $483.8 million in 2024, then decreased by 28.44% to $353.1 million in 2025.
  • Its Liabilities and Shareholders Equity was $353.1 million in Q3 2025, compared to $335.2 million in Q2 2025 and $422.1 million in Q1 2025.